Trials / Recruiting
RecruitingNCT07439458
Tumour Cell Response to Acute Aerobic Exercise in Breast Cancer Survivors: Modulatory Effects of Exercise Type and Intensity
Tumour Cell Response to Acute Aerobic Exercise in Breast Cancer Survivors: Modulatory Effects of Exercise Type and Intensity (TCReX) No: RSU/LSPA-PA-2024/1-0004 is Financed by the Investment of the European Union Recovery and Resilience Facility and the State Budget Within the Project "RSU Internal and RSU With LASE External Consolidation" No. 5.2.1.1.i.0/2/24/I/CFLA/005.
- Status
- Recruiting
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 40 (estimated)
- Sponsor
- Riga Stradins University · Academic / Other
- Sex
- Female
- Age
- 35 Years
- Healthy volunteers
- Accepted
Summary
Cancer has emerged as a prominent cause of mortality in the 21st century, with breast cancer (BC) being the most diagnosed malignancy. Multidisciplinary cancer management has improved survival chances, but side effects and long-term consequences of treatments have significant implications for cancer survivors' health-related quality of life. Exercise is increasingly considered and used in cancer treatment and follow-up. However, studies demonstrating the biological mechanisms underlying the anticarcinogenic effects (ACE) of exercise are insufficient to justify the most appropriate physical activity for different clinical scenarios. Achieving scientific excellence in understanding the ACE of exercise in cancer management is critical to optimize treatment and enhance patients' quality of life.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| OTHER | High intensity continuous exercise | 30 minutes of continuous exercise at 75% of VO2max, additionally 15 minutes of warm-up to reach specific workload. |
| OTHER | Moderate intensity continuous exercise | 30 minutes of continuous exercise at 45% of VO2max, additionally 15 minutes of warm-up to reach specific workload. |
Timeline
- Start date
- 2024-04-01
- Primary completion
- 2026-03-31
- Completion
- 2026-03-31
- First posted
- 2026-02-27
- Last updated
- 2026-02-27
Locations
1 site across 1 country: Latvia
Source: ClinicalTrials.gov record NCT07439458. Inclusion in this directory is not an endorsement.